Drug Profile
B7 immunoglobulin G
Alternative Names: B7-IgG; B7-immunoglobulin G; B7.1-IgG; B7.2-IgGLatest Information Update: 05 Oct 2006
Price :
$50
*
At a glance
- Originator Wyeth
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Oct 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 20 Mar 2002 American Home Products and its subsidiaries Wyeth-Ayerst and Wyeth Lederle are both now called Wyeth
- 24 Sep 2001 Preclinical development for Cancer in USA (Unknown route)